Literature DB >> 14739101

Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors.

Rene Gerolami1, Rathviro Uch, Jamila Faivre, Stephane Garcia, Jean Hardwigsen, Jorge Cardoso, Sylvie Mathieu, Claude Bagnis, Christian Brechot, Patrice Mannoni.   

Abstract

BACKGROUND/AIMS: Gene therapy is a promising approach for treatment of hepatocellular carcinoma (HCC). However, transduction of non-tumoral hepatocytes may lead to severe hepatitis when using suicide gene therapy approaches. The aim of our study was to evaluate the gene transfer efficiency into HCC cells and normal hepatocytes using human immunodeficiency virus (HIV)-derived lentiviral vectors in vitro and in vivo.
METHODS: Lentiviral vectors encoding for the LacZ gene or the fusion gene HSV-Tk/GFP were tested in vitro in human HCC cells and human hepatocytes in primary culture and in vivo in a chemically induced rat model of HCC.
RESULTS: We show that HIV-1-derived lentiviral vectors are efficient in transducing HCC cells in vitro and in vivo. No significant transduction of non-tumorous hepatocytes was observed in vivo whatever the route of administration used. Measurement of tumor growth following direct intratumoral injection of a lentiviral vector containing the HSV-Tk gene and GCV treatment showed a strong antitumoral efficacy in the absence of normal liver toxicity.
CONCLUSIONS: These observations suggest that lentiviral vectors allow an antitumoral effect with low liver toxicity when using suicide gene therapy approach and could be efficient tools for HCC gene therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739101     DOI: 10.1016/j.jhep.2003.10.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model.

Authors:  Florian Graepler; Marie-Luise Lemken; Wolfgang A Wybranietz; Ulrike Schmidt; Irina Smirnow; Christine D Gross; Martin Spiegel; Andrea Schenk; Hansjörg Graf; Ulrike A Lauer; Reinhard Vonthein; Michael Gregor; Sorin Armeanu; Michael Bitzer; Ulrich M Lauer
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

2.  What's New in Transarterial Therapies for Hepatocellular Carcinoma?

Authors:  Benjamin J May; Ravi Murthy; David C Madoff
Journal:  Gastrointest Cancer Res       Date:  2012-05

3.  The EIIAPA chimeric promoter for tumor specific gene therapy of hepatoma.

Authors:  Ya-Ju Hsieh; Fu-Du Chen; Chien-Chih Ke; Hsin-Ell Wang; Chih-Jen Huang; Ming-Feng Hou; Kang-Ping Lin; Juri G Gelovani; Ren-Shyan Liu
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

Review 4.  Management of hepatocellular carcinoma.

Authors:  Janice N Cormier; K Tyson Thomas; Ravi S Chari; C Wright Pinson
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

5.  Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of esophageal squamous cancers.

Authors:  Yaoping Shi; Jianfeng Wang; Zhibin Bai; Yonggang Li; Longhua Qiu; Bo Zhai; Feng Zhang; Xiaoming Yang
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

6.  Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of hepatocellular carcinoma.

Authors:  Jianfeng Wang; Yaoping Shi; Zhibin Bai; Yonggang Li; Longhua Qiu; Guy Johnson; Feng Zhang; Xiaoming Yang
Journal:  Int J Hyperthermia       Date:  2016-09-20       Impact factor: 3.914

Review 7.  Advances in experimental and translational research in the treatment of hepatocellular carcinoma.

Authors:  Travis Kidner; Menghua Dai; Prasad S Adusumilli; Yuman Fong
Journal:  Surg Oncol Clin N Am       Date:  2008-04       Impact factor: 3.495

8.  HSVtk/GCV system on hepatoma carcinoma cells: Construction of the plasmid pcDNA3.1‑pAFP-TK and targeted killing effect.

Authors:  Yong-Fang Li; Yang-Yang Yuan; Ying-Min Zhang; Na Zhao; Qi Zhang; Fan-Xiu Meng; Ran-Peng Gao; Bao-Feng Yu; Yue-Hong Zhang; Rui Guo; Hai-Long Wang; Jun Xie; Jun Xu; Qin Qin; Xiu-Shan Dong
Journal:  Mol Med Rep       Date:  2017-05-31       Impact factor: 2.952

9.  Orthotopic hepatic cancer: radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy.

Authors:  Fu Xiong; Feng Zhang; Yin Jin; Qiaoyou Weng; Jingjing Song; Guofeng Zhou; David Shin; Chuansheng Zheng; Xiaoming Yang
Journal:  Oncotarget       Date:  2017-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.